Changes in Hong Kong stocks | Zhaoyan New Pharmaceutical (06127) rose more than 7% in the intraday period, new drug development is active, experimental monkey resources are tight, and the unit price has reached a high of 200,000 yuan

The Zhitong Finance App learned that Zhaoyan New Pharmaceutical (06127) rose more than 7% in the intraday period. As of press release, it had risen 6.59% to HK$21.66, with a turnover of HK$100 million.

According to the news, according to First Finance, research and development of new drugs is active, and experimental monkey resources have once again become scarce. “Not only are monkeys very expensive now, but more importantly, they are still not available.” As the head of research and development at a biopharmaceutical company, Zhang Ming found himself in a difficult situation of finding monkeys. R&D personnel at another pharmaceutical company said that the price of crab-eating monkeys has increased quite a bit. According to their latest inquiry, the unit price has reached 200,000 yuan. “All CROs (Pharmaceutical R&D Outsourcing) have almost reached their full schedule of experimental monkeys that can be booked this year.”

Western Securities previously pointed out that due to the 6-7 year breeding and expansion cycle of experimental monkeys and the aging of breeding populations, China's endogenous supply of experimental monkey resources shrank. Furthermore, after the COVID-19 pandemic, the country tightened controls on wildlife imports and exports, and the external supply of experimental monkey resources was limited. Future experimental monkey prices are expected to continue to rise against the backdrop of a recovery in industry demand, thus bringing greater profit flexibility to the company through changes in the fair value of biological assets.